within Pharmacolibrary.Drugs.ATC.V;

model V09DB05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.015000000000000001,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09DB05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Technetium (99mTc) sulfur colloid is a radiopharmaceutical agent comprised of technetium-99m labeled sulfur colloid particles. It is primarily used for imaging the reticuloendothelial system, including the liver, spleen, and bone marrow, as well as for sentinel lymph node mapping. It is approved and routinely used for diagnostic imaging in nuclear medicine.</p><h4>Pharmacokinetics</h4><p>No specific pharmacokinetic models with precise parameters (such as volume of distribution and clearance) have been published for technetium (99mTc) sulfur colloid in humans in the literature, likely due to its colloidal particle nature and predominant localization by phagocytosis in the reticuloendothelial system. The following parameters are estimated based on general clinical and nuclear medicine references.</p><h4>References</h4><ol><li><p>Stavropoulos, SW, et al., &amp; Alavi, A (2006). Detection of endoleaks after endovascular aneurysm repair with use of technetium-99m sulfur colloid and (99m)Tc-labeled red blood cell scans. <i>Journal of vascular and interventional radiology : JVIR</i> 17(11 Pt 1) 1739–1743. DOI:<a href=&quot;https://doi.org/10.1097/01.RVI.0000241892.81074.1A&quot;>10.1097/01.RVI.0000241892.81074.1A</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17142703/&quot;>https://pubmed.ncbi.nlm.nih.gov/17142703</a></p></li><li><p>Alkandari, AM, et al., &amp; Alsayed, YM (2020). Preclinical Assessment of . <i>Journal of nuclear medicine technology</i> 48(3) 269–273. DOI:<a href=&quot;https://doi.org/10.2967/jnmt.119.239756&quot;>10.2967/jnmt.119.239756</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32518123/&quot;>https://pubmed.ncbi.nlm.nih.gov/32518123</a></p></li><li><p>Fokin, AA, et al., &amp; Masters, TN (2000). Transport of viral-size particulate matter after intravenous versus intralymphatic entry. <i>Microcirculation (New York, N.Y. : 1994)</i> 7(5) 357–365. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11079253/&quot;>https://pubmed.ncbi.nlm.nih.gov/11079253</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09DB05;
